GPER-L2
Introduction[edit | edit source]
GPER-L2 (G Protein-Coupled Estrogen Receptor 2) is a member of the G protein-coupled receptor (GPCR) family, which is involved in mediating the effects of estrogen in various tissues. This receptor is distinct from the classical nuclear estrogen receptors, ERα and ERβ, and is primarily located on the cell membrane, where it can rapidly activate intracellular signaling pathways.
Structure[edit | edit source]
GPER-L2 is a transmembrane protein that spans the cell membrane seven times, a characteristic feature of GPCRs. The receptor is composed of an extracellular N-terminus, seven transmembrane helices, and an intracellular C-terminus. The binding of estrogen to GPER-L2 induces a conformational change that activates associated G proteins, leading to downstream signaling events.
Function[edit | edit source]
GPER-L2 plays a crucial role in mediating non-genomic signaling pathways of estrogen. Upon activation by estrogen, GPER-L2 can:
- Activate adenylate cyclase, increasing intracellular cAMP levels.
- Stimulate the release of calcium ions from intracellular stores.
- Activate the PI3K/Akt and MAPK/ERK signaling pathways.
These pathways are involved in various cellular processes, including cell proliferation, apoptosis, and migration. GPER-L2 is implicated in cardiovascular function, neuroprotection, and cancer progression.
Clinical Significance[edit | edit source]
GPER-L2 has been studied for its role in various diseases:
- Cardiovascular Disease: GPER-L2 activation has been shown to have protective effects on the cardiovascular system, including vasodilation and anti-inflammatory effects.
- Cancer: GPER-L2 is expressed in several types of cancer, including breast and ovarian cancer. It may contribute to cancer cell proliferation and metastasis.
- Neuroprotection: GPER-L2 activation has neuroprotective effects, potentially offering therapeutic benefits in neurodegenerative diseases.
Research and Development[edit | edit source]
Ongoing research is focused on developing selective agonists and antagonists for GPER-L2 to better understand its role in health and disease. These compounds could serve as potential therapeutic agents for conditions where GPER-L2 is implicated.
Also see[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD